FDA Acceptance of Supplemental NDA for ZIAC by Teva
The FDA has accepted a supplemental NDA for ZIAC, which contains bisoprolol fumarate and hydrochlorothiazide.
Therapeutic Area
Therapeutic area intelligence for Hypertension with 17 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.